Slip.stream is a technology company.
Slip.stream has raised $11.0M across 2 funding rounds.
Slip.stream has raised $11.0M in total across 2 funding rounds.
Slip.stream has raised $11.0M in total across 2 funding rounds.
Slip.stream's investors include LightShed Ventures, Primetime Partners, Vayner RSE, Deciens Capital, Plug & Play Ventures, QED Investors, Guilherme Bonifacio.
Slipstream IT LLC (accessible at slip.stream-it.com) is a privately-held technology company founded in 2020, specializing as a trusted IT partner exclusively for the life sciences industry, including biotech, pharmaceuticals, and clinical research organizations (CROs).[1][2][3] It provides pragmatic, end-to-end solutions—such as IT outsourcing, consulting, Veeva Commercial implementations, data governance, and commercial operations—that unite speed, compliance, and foresight to accelerate research, optimize time-to-market, and improve patient outcomes for over 200 organizations across 25+ countries.[1][2] With headquarters in Blue Bell, Pennsylvania, ~295 employees, and ~$71.9 million in revenue, Slipstream serves emerging biotechs, small/mid-sized pharma, and large pharma by simplifying complex challenges across the product lifecycle, from PMO and sales operations to end-user services and AI-ready data foundations.[1][2][4]
The company emphasizes deep domain expertise in life sciences IT, delivering near-shore "white glove" service via global delivery centers, and positions itself as both a strategic collaborator for complex challenges and a reliable ITO provider for day-to-day operations.[1][2]
Slipstream IT LLC was founded in 2020 as a specialized technology services firm targeting the life sciences sector, building on decades of collective expertise from its team in IT service management, delivery, biotech, and pharmaceuticals.[1][3] While specific founders are not detailed in available sources, key leaders include Laurie (joined December 2020 with 25+ years in IT service management for life sciences) and Nitin (joined September 2021 with 20+ years, now leading the global Veeva Commercial practice for CRM, Network, Align, and ETL integrations).[1]
The company emerged amid growing demands for compliant, scalable IT in life sciences, quickly gaining traction by co-authoring studies (e.g., a cost study on Hereditary Hemorrhagic Telangiectasia published in the American Journal of Hematology) and expanding practices like CRO support and Veeva solutions, establishing trust with 200+ clients.[2] Its evolution reflects a focus on turning unique life sciences challenges into opportunities for progress, with rapid scaling to ~295 employees and $71.9M revenue.[2][4]
Slipstream rides the convergence of life sciences and digital transformation, where AI, data analytics, and cloud tools (e.g., Veeva suites) are critical for accelerating drug discovery, clinical trials, and commercialization amid rising R&D costs and regulatory pressures.[1][2] Its timing aligns with post-2020 biotech boom—fueled by mRNA tech, personalized medicine, and AI-driven insights—enabling SMB pharmas and CROs to scale without building in-house IT expertise.[2][3]
Market forces like talent shortages in compliant IT, exploding data volumes from trials, and demands for faster market entry (e.g., via unified CRM and ETL) favor Slipstream's model, influencing the ecosystem by standardizing Veeva deployments and data governance for 200+ firms, indirectly boosting innovation in therapies like those for rare diseases.[1][2] As a non-equity services player, it democratizes tech access for smaller players, amplifying overall sector efficiency.
Slipstream is poised for continued expansion in the life sciences IT services market, projected to grow with AI integration in drug development and rising outsourcing (e.g., Veeva ecosystem dominance).[1][2] Next steps likely include deeper AI/data analytics offerings, geographic scaling beyond near-shore centers, and more thought leadership to capture large pharma deals amid ~$72M revenue momentum.[2][4]
Shaping trends—regulatory evolution (e.g., FDA digital guidelines), biotech funding cycles, and real-world evidence needs—will drive demand; Slipstream's compliant speed positions it to evolve from ITO provider to indispensable AI-enablement partner, further accelerating life-changing missions as it started: expertise delivered, research unbound.[1][2]
Slip.stream has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M Series A in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $8.0M Series A | LightShed Ventures, Primetime Partners, Vayner RSE | |
| Jul 1, 2021 | $3.0M Seed | Deciens Capital, LightShed Ventures, Plug & Play Ventures, Primetime Partners, QED Investors, Vayner RSE, Guilherme Bonifacio |